TickerFacts.

Incyte Corp (INCY): Cash & Equivalents

Annual figures by period end, from SEC filings.

$3.10B
As of 2025-12-31
$3.46B
As of 2026-03-31
+1.6%
3-year compound annual growth
+15.4%
5-year compound annual growth
+19.5%
10-year compound annual growth
$3.21B2009-12-31: $449.82M2010-12-31: $417.91M2011-12-31: $273.16M2012-12-31: $224.06M2013-12-31: $471.43M2014-12-31: $452.30M2015-12-31: $521.44M2016-12-31: $652.34M2017-12-31: $899.51M2018-12-31: $1.16B2019-12-31: $1.83B2020-12-31: $1.51B2021-12-31: $2.06B2022-12-31: $2.95B2023-12-31: $3.21B2024-12-31: $1.69B2025-12-31: $3.10B$3.10B
2009-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$3.10B+83.5%2026-02-10, Balance as of period end
2024-12-31$1.69B-47.5%2026-02-10, Balance as of period end
2023-12-31$3.21B+8.9%2025-02-10, Balance as of period end
2022-12-31$2.95B+43.5%2024-02-13, Balance as of period end
2021-12-31$2.06B+36.0%2023-02-07, Balance as of period end
2020-12-31$1.51B-17.4%2022-02-08, Balance as of period end
2019-12-31$1.83B+57.4%2021-02-09, Balance as of period end
2018-12-31$1.16B+29.4%2020-02-13, Balance as of period end
2017-12-31$899.51M+37.9%2019-02-14, Balance as of period end
2016-12-31$652.34M+25.1%2018-02-15, Balance as of period end
2015-12-31$521.44M+15.3%2018-02-15, Balance as of period end
2014-12-31$452.30M-4.1%2017-02-14, Balance as of period end
2013-12-31$471.43M+110.4%2016-02-12, Balance as of period end
2012-12-31$224.06M-18.0%2015-02-17, Balance as of period end
2011-12-31$273.16M-34.6%2014-02-21, Balance as of period end
2010-12-31$417.91M-7.1%2013-02-21, Balance as of period end
2009-12-31$449.82Mn/a2012-02-22, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Incyte Corp (INCY)2025-12-31$3.10B+83.5%
Charles River Laboratories International, Inc. (CRL)2025-12-27$213.77M+9.8%
Icon PLC (ICLR)2025-12-31$647.29M+20.1%
Medpace Holdings, Inc. (MEDP)2025-12-31$497.05M-25.8%
Iqvia Holdings Inc. (IQV)2025-12-31$1.98B+16.3%
NRC Health (NRC)2025-12-31$4.14M-2.2%
MaxCyte, Inc. (MXCT)2025-12-31$20.07M-28.0%
OmniAb, Inc. (OABI)2025-12-31$25.52M-7.5%
Foxo Technologies Inc. (FOXO)2025-12-31$207.5K+203.9%

Compare INCY, CRL, ICLR, MEDP side by side · Screen every company in Services-Commercial Physical & Biological Research ↗